MUDr. Jaroslav Mares - ordinace pro TBC a respiracní nemoci

The clinic in Strakonice concentrates on asthma and its severe eosinophilic variants, evaluating novel treatments aimed at better symptom control and fewer flare‑ups.

• Targeted biologic agents for T2‑high asthma
• Strategies to reduce eosinophil‑driven inflammation
• Optimization of inhaled corticosteroid regimens
• Biomarker‑guided patient selection

Across eight trials and two investigators, the site delivers critical insights into real‑world effectiveness for patients across the Czech Republic.

MUDr. Jaroslav Mares – ordinace pro TBC a respiracní nemoci advances care for chronic obstructive pulmonary disease and chronic bronchitis, testing inhaled combinations that aim to improve lung function and lower exacerbation risk.

• Fixed‑dose triple therapy versus dual therapy
• Enhancements in pre‑dose FEV1 measurements
• Reduction of moderate and severe COPD exacerbations
• Ongoing safety monitoring in long‑term use

The research programme supports regional treatment guidelines and offers patients access to emerging inhaled options.

Dedicated studies explore therapies for severe eosinophilic asthma, focusing on long‑term safety and sustained reduction of exacerbations through advanced antibodies and oral agents.

• Anti‑TSLP monoclonal antibodies
• Long‑acting injectable biologics
• Modulation of eosinophil counts
• Extended open‑label safety extensions

Participants benefit from continuous follow‑up, providing the site with robust data on durability of response.

The research team evaluates non‑invasive markers such as fractional exhaled nitric oxide to identify the T2‑high asthma phenotype and personalize therapeutic choices.

• FeNO monitoring to gauge airway inflammation
• Phenotype‑driven treatment algorithms
• Integration of biomarker data into clinical decision‑making
• Development of predictive tools for exacerbation risk

These efforts enhance diagnostic precision and support tailored treatment pathways for respiratory patients.